Keywords
Last Name
Institution

M. Rita I. Young

Title
InstitutionMedical University of South Carolina
DepartmentOtolaryngology - Head and Neck Surgery
AddressP.O. Box MSC 550
STB 153
114 Doughty St.
Phone843-792-9953
Fax843-876-5384
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Young's research focus is on immune regulation in patients with squamous cell carcinoma of the head and neck. The studies in her laboratory have identified several mechanisms to overcome immune dysfunction so that immune vaccines can be effective.

    Collapse keywords
    Oncology, with emphasis on oral cancers, Cancer-induced immune suppression, Immunotherapy for treatment of cancer

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Young MRI. Redirecting the focus of cancer immunotherapy to premalignant conditions. Cancer Lett. 2017 04 10; 391:83-88. PMID: 28130162.
      View in: PubMed
    2. Johnson SD, Levingston C, Young MR. Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells. Anticancer Res. 2016 Jul; 36(7):3261-70. PMID: 27354582.
      View in: PubMed
    3. Young MR. Th17 Cells in Protection from Tumor or Promotion of Tumor Progression. J Clin Cell Immunol. 2016 Jun; 7(3):431. PMID: 27453801.
      View in: PubMed
    4. Wang Z, Young MR. PTSD, a Disorder with an Immunological Component. Front Immunol. 2016; 7:219. PMID: 27375619.
      View in: PubMed
    5. Wang Z, Mandel H, Levingston CA, Young MRI. An exploratory approach demonstrating immune skewing and a loss of coordination among cytokines in plasma and saliva of Veterans with combat-related PTSD. Hum Immunol. 2016 Aug; 77(8):652-657. PMID: 27216157.
      View in: PubMed
    6. Young MR, Levingston CA, Johnson SD. Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer. Int J Cancer. 2016 May 15; 138(10):2487-98. PMID: 26756968.
      View in: PubMed
    7. Young MR, Levingston C, Johnson SD. Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1a,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis. Cancers (Basel). 2015 Jun 25; 7(3):1109-24. PMID: 26120967.
      View in: PubMed
    8. Woodford D, Johnson SD, De Costa AM, Young MR. An Inflammatory Cytokine Milieu is Prominent in Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous Cell Carcinoma. J Clin Cell Immunol. 2014 Jun; 5(3). PMID: 25419481.
      View in: PubMed
    9. Johnson SD, De Costa AM, Young MR. Effect of the premalignant and tumor microenvironment on immune cell cytokine production in head and neck cancer. Cancers (Basel). 2014 Apr 02; 6(2):756-70. PMID: 24698959.
      View in: PubMed
    10. Vielma SA, Klein RL, Levingston CA, Young MR. Skewing of immune cell cytokine production by mediators from adipocytes and endothelial cells. Adipocyte. 2014 Apr 01; 3(2):126-31. PMID: 24719786.
      View in: PubMed
    11. Young MR, Day TA. Immune regulatory activity of vitamin d3 in head and neck cancer. Cancers (Basel). 2013 Aug 14; 5(3):1072-85. PMID: 24202334.
      View in: PubMed
    12. Vielma SA, Klein RL, Levingston CA, Young MR. Premalignant lesions skew spleen cell responses to immune modulation by adipocytes. Anticancer Res. 2013 May; 33(5):1809-18. PMID: 23645725.
      View in: PubMed
    13. Vielma SA, Klein RL, Levingston CA, Young MR. Adipocytes as immune regulatory cells. Int Immunopharmacol. 2013 Jun; 16(2):224-31. PMID: 23587489.
      View in: PubMed
    14. Young MR. Endothelial cells in the eyes of an immunologist. Cancer Immunol Immunother. 2012 Oct; 61(10):1609-16. PMID: 22903347.
      View in: PubMed
    15. De Costa AM, Justis DN, Schuyler CA, Young MR. Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response. Int Immunopharmacol. 2012 Jul; 13(3):322-30. PMID: 22609090.
      View in: PubMed
    16. Walker DD, Reeves TD, de Costa AM, Schuyler C, Young MR. Immunological modulation by 1a,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck. Cytokine. 2012 Jun; 58(3):448-54. PMID: 22450225.
      View in: PubMed
    17. De Costa AM, Schuyler CA, Walker DD, Young MR. Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2012 Jun; 61(6):927-39. PMID: 22116344.
      View in: PubMed
    18. Walsh JE, Young MR. TGF-beta regulation of focal adhesion proteins and motility of premalignant oral lesions via protein phosphatase 1. Anticancer Res. 2011 Oct; 31(10):3159-64. PMID: 21965722.
      View in: PubMed
    19. De Costa AM, Young MR. Immunotherapy for head and neck cancer: advances and deficiencies. Anticancer Drugs. 2011 Aug; 22(7):674-81. PMID: 21037467.
      View in: PubMed
    20. Walsh JE, Young MR. Interrelationship between protein phosphatase 1 and TGF-{beta} in regulating motility and cytoskeletal architecture of endothelial cells. Anticancer Res. 2010 Dec; 30(12):4861-6. PMID: 21187463.
      View in: PubMed
    21. Mailloux AW, Clark AM, Young MR. NK depletion results in increased CCL22 secretion and Treg levels in Lewis lung carcinoma via the accumulation of CCL22-secreting CD11b+CD11c+ cells. Int J Cancer. 2010 Dec 01; 127(11):2598-611. PMID: 20198623.
      View in: PubMed
    22. Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol. 2010 Jul; 71(7):659-65. PMID: 20438786.
      View in: PubMed
    23. Mulligan JK, Rosenzweig SA, Young MR. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother. 2010 Feb-Mar; 33(2):126-35. PMID: 20145550.
      View in: PubMed
    24. Mulligan JK, Young MR. Tumors induce the formation of suppressor endothelial cells in vivo. Cancer Immunol Immunother. 2010 Feb; 59(2):267-77. PMID: 19669642.
      View in: PubMed
    25. Mailloux AW, Young MR. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol. 2010; 30(5):435-47. PMID: 21083525.
      View in: PubMed
    26. Clark JI, Eisner RM, Hofmeister C, Norton J, Thomas S, Choudhury A, Petruzzelli G, Lathers D, Young MR, Lau A, Emami B. Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer. Am J Clin Oncol. 2009 Aug; 32(4):396-400. PMID: 19415031.
      View in: PubMed
    27. Mailloux AW, Young MR. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol. 2009 Mar 01; 182(5):2753-65. PMID: 19234170.
      View in: PubMed
    28. Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA, Young MR. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum Immunol. 2009 Jun; 70(6):375-82. PMID: 19480853.
      View in: PubMed
    29. Kulbersh JS, Day TA, Gillespie MB, Young MR. 1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells. Otolaryngol Head Neck Surg. 2009 Feb; 140(2):235-40. PMID: 19201295.
      View in: PubMed
    30. Mulligan JK, Lathers DM, Young MR. Tumors skew endothelial cells to disrupt NK cell, T-cell and macrophage functions. Cancer Immunol Immunother. 2008 Jul; 57(7):951-61. PMID: 18058097.
      View in: PubMed
    31. Young MR. Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer. J Immunother. 2008 Feb-Mar; 31(2):148-56. PMID: 18481384.
      View in: PubMed
    32. Matthews CP, Colburn NH, Young MR. AP-1 a target for cancer prevention. Curr Cancer Drug Targets. 2007 Jun; 7(4):317-24. PMID: 17979626.
      View in: PubMed
    33. Walsh JE, Lathers DM, Chi AC, Gillespie MB, Day TA, Young MR. Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol. 2007 Jun; 8(3):227-38. PMID: 17712533.
      View in: PubMed
    34. Young MR, Neville BW, Chi AC, Lathers DM, Gillespie MB, Day TA. Autocrine motility-stimulatory pathways of oral premalignant lesion cells. Clin Exp Metastasis. 2007; 24(2):131-9. PMID: 17370039.
      View in: PubMed
    35. Kanabrocki EL, Ryan MD, Lathers D, Achille N, Young MR, Cauteren JV, Foley S, Johnson MC, Friedman NC, Siegel G, Nemchausky BA. Circadian distribution of serum cytokines in multiple sclerosis. Clin Ter. 2007 Mar-Apr; 158(2):157-62. PMID: 17566518.
      View in: PubMed
    36. Rashid RM, Lee JM, Fareed J, Young MR. In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice. Immunol Invest. 2007; 36(2):183-201. PMID: 17365019.
      View in: PubMed
    37. Gillespie MB, Moody MW, Lee FS, Poole LJ, Hornig JD, Lathers D, Young MR, Day TA. Head and neck cancer recurrence and mortality in nonselective cyclooxygenase inhibitor users. Arch Otolaryngol Head Neck Surg. 2007 Jan; 133(1):28-31. PMID: 17224518.
      View in: PubMed
    38. Young MR, Neville BW, Chi AC, Lathers DM, Boyd Gillespie M, Day TA. Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2007 Jul; 56(7):1077-86. PMID: 17096152.
      View in: PubMed
    39. Yen KL, Horner MJ, Reed SG, Daguise VG, Bolick-Aldrich SW, Young MR, Day TA, Wood PA, Hebert JR. Head and neck cancer disparities in South Carolina: descriptive epidemiology, early detection, and special programs. J S C Med Assoc. 2006 Aug; 102(7):192-200. PMID: 17319230.
      View in: PubMed
    40. Young MR. Cytokine-containing gelfoam implants at a postsurgical tumor excision site to stimulate local immune reactivity. Int J Cancer. 2006 Jul 01; 119(1):133-8. PMID: 16450395.
      View in: PubMed
    41. Woodworth BA, Lathers D, Neal JG, Skinner M, Richardson M, Young MR, Schlosser RJ. Immunolocalization of surfactant protein A and D in sinonasal mucosa. Am J Rhinol. 2006 Jul-Aug; 20(4):461-5. PMID: 16955780.
      View in: PubMed
    42. Young MR. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck. 2006 May; 28(5):462-70. PMID: 16284974.
      View in: PubMed
    43. Rashid RM, Lee JM, Fareed J, Young MR. In vivo heparan sulfate treatment alters the immune response of normal and LLC-bearing mice. Immunopharmacol Immunotoxicol. 2006; 28(1):67-79. PMID: 16684668.
      View in: PubMed
    44. Young MR, Lathers DM. Combination docetaxel plus vitamin D(3) as an immune therapy in animals bearing squamous cell carcinomas. Otolaryngol Head Neck Surg. 2005 Oct; 133(4):611-8. PMID: 16213938.
      View in: PubMed
    45. Young MR, Cigal M. Tumor skewing of CD34+ cell differentiation from a dendritic cell pathway into endothelial cells. Cancer Immunol Immunother. 2006 May; 55(5):558-68. PMID: 16025265.
      View in: PubMed
    46. Rashid RM, Achille NJ, Lee JM, Lathers DM, Young MR. Decreased T-cell proliferation and skewed immune responses in LLC-bearing mice. J Environ Pathol Toxicol Oncol. 2005; 24(3):175-92. PMID: 16050802.
      View in: PubMed
    47. Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 2004 Nov; 131(5):573-6. PMID: 15523428.
      View in: PubMed
    48. Young MR. Tumor skewing of CD34+ progenitor cell differentiation into endothelial cells. Int J Cancer. 2004 Apr 20; 109(4):516-24. PMID: 14991572.
      View in: PubMed
    49. Lathers DM, Young MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine. 2004 Mar 07; 25(5):220-8. PMID: 15036248.
      View in: PubMed
    50. Young MR. Tumor-derived prostaglandin E2 and transforming growth factor-beta stimulate endothelial cell motility through inhibition of protein phosphatase-2A and involvement of PTEN and phosphatidylinositide 3-kinase. Angiogenesis. 2004; 7(2):123-31. PMID: 15516833.
      View in: PubMed
    51. Romashko AA, Young MR. Protein phosphatase-2A maintains focal adhesion complexes in keratinocytes and the loss of this regulation in squamous cell carcinomas. Clin Exp Metastasis. 2004; 21(4):371-9. PMID: 15554394.
      View in: PubMed
    52. Lathers DM, Achille NJ, Young MR. Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol. 2003 Dec; 64(12):1160-6. PMID: 14630398.
      View in: PubMed
    53. Lathers DM, Clark JI, Achille NJ, Young MR. Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3. Cancer Immunol Immunother. 2004 May; 53(5):422-30. PMID: 14648070.
      View in: PubMed
    54. Young MR. Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2004 May; 53(5):375-82. PMID: 14634795.
      View in: PubMed
    55. Brockenbrough JM, Marzo S, Wurster R, Young MR. Bone wax prevents nystagmus after labyrinthine fenestration in guinea pigs. Otolaryngol Head Neck Surg. 2003 May; 128(5):726-31. PMID: 12748568.
      View in: PubMed
    56. Jackson JL, Young MR. Protein phosphatase-2A regulates protein tyrosine phosphatase activity in Lewis lung carcinoma tumor variants. Clin Exp Metastasis. 2003; 20(4):357-64. PMID: 12856723.
      View in: PubMed
    57. Banich JC, Kolesiak K, Young MR. Chemoattraction of CD34+ progenitor cells and dendritic cells to the site of tumor excision as the first step of an immunotherapeutic approach to target residual tumor cells. J Immunother. 2003 Jan-Feb; 26(1):31-40. PMID: 12514427.
      View in: PubMed
    58. Lathers DM, Achille N, Young MR. Dendritic cell development from mobilized peripheral blood CD34+ cells. Methods Mol Biol. 2003; 215:409-15. PMID: 12512316.
      View in: PubMed
    59. Young MR, Liu SW, Meisinger J. Protein phosphatase-2A restricts migration of Lewis lung carcinoma cells by modulating the phosphorylation of focal adhesion proteins. Int J Cancer. 2003 Jan 01; 103(1):38-44. PMID: 12455051.
      View in: PubMed
    60. Young MR, Kolesiak K, Meisinger J. Protein phosphatase-2A regulates endothelial cell motility and both the phosphorylation and the stability of focal adhesion complexes. Int J Cancer. 2002 Jul 20; 100(3):276-82. PMID: 12115541.
      View in: PubMed
    61. Wachter BG, Leonetti JP, Lee JM, Wurster RD, Young MR. Silver nitrate injury in the rat sciatic nerve: a model of facial nerve injury. Otolaryngol Head Neck Surg. 2002 Jul; 127(1):48-54. PMID: 12161730.
      View in: PubMed
    62. Ziroli NE, Na H, Chow JM, Stankiewicz JA, Samter M, Young MR. Aspirin-sensitive versus non-aspirin-sensitive nasal polyp patients: analysis of leukotrienes/Fas and Fas-ligand expression. Otolaryngol Head Neck Surg. 2002 Feb; 126(2):141-6. PMID: 11870343.
      View in: PubMed
    63. Shafer LL, McNulty JA, Young MR. Brain activation of monocyte lineage cells: brain-derived soluble factors differentially regulate BV2 microglia and peripheral macrophage immune functions. Neuroimmunomodulation. 2002-2003; 10(5):283-94. PMID: 12759565.
      View in: PubMed
    64. Shafer LL, McNulty JA, Young MR. Brain activation of monocyte-lineage cells: involvement of interleukin-6. Neuroimmunomodulation. 2002-2003; 10(5):295-304. PMID: 12759566.
      View in: PubMed
    65. Jackson JL, Young MR. Protein phosphatase-2A modulates the serine and tyrosine phosphorylation of paxillin in Lewis lung carcinoma tumor variants. Clin Exp Metastasis. 2002; 19(5):409-15. PMID: 12198769.
      View in: PubMed
    66. Shafer LL, McNulty JA, Young MR. Assessment of melatonin's ability to regulate cytokine production by macrophage and microglia cell types. J Neuroimmunol. 2001 Nov 01; 120(1-2):84-93. PMID: 11694323.
      View in: PubMed
    67. Lathers DM, Clark JI, Achille NJ, Young MR. Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients. Hum Immunol. 2001 Nov; 62(11):1282-93. PMID: 11704292.
      View in: PubMed
    68. Lathers DM, Achille N, Kolesiak K, Hulett K, Sparano A, Petruzzelli GJ, Young MR. Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells. Otolaryngol Head Neck Surg. 2001 Sep; 125(3):205-12. PMID: 11555755.
      View in: PubMed
    69. Young MR, Kolesiak K, Achille NJ, Meisinger J, Gonzalez E, Liu SW, Wrone-Smith T, Lathers DM. Impact of aging on immune modulation by tumor. Cancer Immunol Immunother. 2001 Aug; 50(6):315-20. PMID: 11570585.
      View in: PubMed
    70. Fowler SS, Leonetti JP, Banich JC, Lee JM, Wurster R, Young MR. Duration of neuronal stretch correlates with functional loss. Otolaryngol Head Neck Surg. 2001 Jun; 124(6):641-4. PMID: 11391254.
      View in: PubMed
    71. Young MR, Petruzzelli GJ, Kolesiak K, Achille N, Lathers DM, Gabrilovich DI. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34(+) progenitor cells. Hum Immunol. 2001 Apr; 62(4):332-41. PMID: 11295465.
      View in: PubMed
    72. Pandit R, Lathers DM, Beal NM, Garrity T, Young MR. CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer. Ann Otol Rhinol Laryngol. 2000 Aug; 109(8 Pt 1):749-54. PMID: 10961808.
      View in: PubMed
    73. Witt CJ, Gabel SP, Meisinger J, Werra G, Liu SW, Young MR. Interrelationship between protein phosphatase-2A and cytoskeletal architecture during the endothelial cell response to soluble products produced by human head and neck cancer. Otolaryngol Head Neck Surg. 2000 May; 122(5):721-7. PMID: 10793354.
      View in: PubMed
    74. Young MR. Chemokines and cancer Arch Pathol Lab Med. 2000 Apr; 124(4):642. PMID: 10747331.
      View in: PubMed
    75. Prechel MM, Ding C, Washington RL, Kolodziej MS, Young MR. In vivo indomethacin treatment causes microglial activation in adult mice. Neurochem Res. 2000 Mar; 25(3):357-62. PMID: 10761979.
      View in: PubMed
    76. Donzelli J, Leonetti JP, Wurster RD, Lee JM, Young MR. Neuroprotection due to irrigation during bipolar cautery. Arch Otolaryngol Head Neck Surg. 2000 Feb; 126(2):149-53. PMID: 10680864.
      View in: PubMed
    77. Young MR, Liu SW, Meisinger J. Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells. Clin Exp Metastasis. 2000; 18(5):407-13. PMID: 11467773.
      View in: PubMed
    78. Wiers KM, Lathers DM, Wright MA, Young MR. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. J Immunother. 2000 Jan; 23(1):115-24. PMID: 10687144.
      View in: PubMed
    79. Lathers DM, Lubbers E, Beal NM, Wright MA, Young MR. Cultures derived from peripheral blood CD34+ progenitor cells of head and neck cancer patients and from cord blood are functionally different. Hum Immunol. 1999 Dec; 60(12):1207-15. PMID: 10626734.
      View in: PubMed
    80. Young MR, Wright MA, Vellody K, Lathers DM. Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. Int J Immunopharmacol. 1999 Oct; 21(10):675-88. PMID: 12609462.
      View in: PubMed
    81. Young MR, Kolesiak K, Wright MA, Gabrilovich DI. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin Exp Metastasis. 1999; 17(10):881-8. PMID: 11089887.
      View in: PubMed
    Young's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _